This approach combined with the complexity of biological systems restricts current, one-off efforts to modifying only a small set of genes and constructing simple, isolated genetic circuits and metabolic pathways.
Merck is taking a different approach, betting that an especially deep understanding of a biological pathway will allow it to design better clinical trials.